Presence of Legacy and Emerging PFAS in Human Liver Specimens Banked in the United States from 2000 to 2024 - PubMed
4 hours ago
- #PFAS
- #biomonitoring
- #liver toxicity
- PFAS were found in 210 out of 211 human liver samples collected from 2000 to 2024, with 15 compounds frequently detected.
- Total PFAS concentrations decreased by 94% over 24 years in weighted regression, and by 68% after adjusting for factors like age, sex, and liver health.
- Since 2019, PFAS concentrations varied up to 950-fold, and the profile shifted from sulfonates and carboxylates to more sulfonamides and fluorotelomers.
- Sampling year was the strongest predictor of PFAS levels, with age positively linked to long-chain PFAS, likely due to long elimination half-lives.
- Males had higher concentrations of certain PFAS, while females had higher levels of 8:2 fluorotelomer sulfonic acid.
- Nonalcoholic fatty liver disease was associated with lower concentrations of seven PFAS.
- Targeted PFAS accounted for less than 10% of extractable organofluorine, indicating most PFAS in livers are unmonitored, highlighting regulatory gaps.